Identification of Flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 202-214

  Zhang, Peng Fei ^a   Zeng, Gu Qing ^a,b   Hu, Rong ^a   Li, Cui ^a   Yi, Hong ^a   Li, Mao Yu ^a   Li, Xin Hui ^a   Qu, Jia Quan ^a   Wan, Xun Xun ^a   He, Qiu Yan ^a   Li, Jian Huang ^a   Chen, Yu ^a   Ye, Xu ^a   Li, Jiao Yang ^a   Wang, Yuan Yuan ^a   Feng, Xue Ping ^a   Xiao, Zhi Qiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

2D LC MS MS; ITRAQ; Lung adenocarcinoma; Plasma membrane proteins; Tumor biomarkers

Indexed keywords

CAVEOLIN 1; CELL MEMBRANE PROTEIN; FLOTILLIN 1;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL MEMBRANE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; PURIFICATION; UPREGULATION; VALIDATION STUDY; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; CELL MEMBRANE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; SURVIVAL RATE; UP-REGULATION;

EID: 84870390447     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.08.021     Document Type: Article

References (58)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Yang L., Parkin D.M., Li L.D., Chen Y.D., Bray F. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 2004, 90:2157-2166.
3. Howe H.L., Wingo P.A., Thun M.J., Ries L.A., Rosenberg H.M., Feigal E.G., et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001, 93:824-842.
4. Little A.G., Gay E.G., Gaspar L.E., Stewart A.K. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007, 57:253-260.
5. Jemal A., Siegel R., Ward E., Murray T., Xu J., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
6. Borczuk A.C., Kim H.K., Yegen H.A., Friedman R.A., Powell C.A. Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 2005, 172:729-737.
7. Shibata T., Uryu S., Kokubu A., Hosoda F., Ohki M., Fong K.M. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 2005, 11:6177-6185.
8. Larsen J.E., Pavey S.J., Passmore L.H., Bowman R.V., Hayward N.K., Matsuno Y., et al. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007, 13:2946-2954.
9. Nakamura N., Kobayashi K., Nakamoto M., Kohno T., Sasaki H., Matsuno Y., et al. Identification of tumor markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene 2006, 25:4245-4255.
10. Tian T., Hao J., Xu A., Hao J., Luo C., Liu C., et al. Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci 2007, 98:1265-1274.
11. Chen G., Gharib T.G., Huang C.C., Thomas D.G., Shedden K.A., Taylor J.M., et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002, 8(7):2298-2305.
12. Chen G., Gharib T.G., Thomas D.G., Huang C.C., Misek D.E., Kuick R.D., et al. Proteomic analysis of eIF-5A in lung adenocarcinomas. Proteomics 2003, 3:496-504.
13. Rho J.H., Roehrl M.H., Wang J.Y. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 2009, 8:5610-5618.
14. Liu Y.F., Xiao Z.Q., Li M.X., Li M.Y., Zhang P.F., Li C., et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol 2009, 2(1):54-64.
15. Liu Y.F., Zhang P.F., Li M.Y., Li Q.Q., Chen Z.C. Identification of annexin A1 as a proinvasive and prognostic factor for lung adenocarcinoma. Clin Exp Metastasis 2011, 28:413-425.
16. Emmott E., Wise H., Loucaides E.M., Matthews D.A., Digard P., Hiscox J.A. Quantitative proteomics using SILAC coupled to LC-MS/MS reveals changes in the nucleolar proteome in influenza A virus-infected cells. J Proteome Res 2010, 9:5335-5345.
17. Qattan A.T., Mulvey C., Crawford M., Natale D.A., Godovac-Zimmermann J. Quantitative organelle proteomics of MCF-7 breast cancer cells reveals multiple subcellular locations for proteins in cellular functional processes. J Proteome Res 2010, 9:495-508.
18. Wu C.C., MacCoss M.J., Howell K.E., Yates J.R. A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 2003, 21:532-538.
19. Wu C.C., Yates J.R. The application of mass spectrometry to membrane proteomics. Nat Biotechnol 2003, 21:262-267.
20. Dowling P., Meleady P., Dowd A., Henry M., Glynn S., Clynes M. Proteomic analysis of isolated membrane fractions from superinvasive cancer cells. Biochim Biophys Acta 2007, 1774:93-101.
21. Liang X., Zhao J., Hajivandi M., Wu R., Tao J., Amshey J.W., et al. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. J Proteome Res 2006, 5:2632-2641.
22. Stockwin L.H., Blonder J., Bumke M.A., Lucas D.A., Chan K.C., Conrads T., et al. Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J Proteome Res 2006, 5:2996-3007.
23. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
24. Oh P., Li Y., Yu J., Durr E., Krasinska K.M., Carver L.A., et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004, 429:629-635.
25. Cao R., Li X., Liu Z., Peng X., Hu W., Wang X., et al. Integration of a two-phase partition method into proteomics research on rat liver plasma membrane proteins. J Proteome Res 2006, 5:634-642.
26. Zeng G.Q., Zhang P.F., Deng X., Yu F.L., Li C., Xu Y., et al. Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics 2012, 11(6). [M111.013946].
27. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:P3.
28. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
29. Krogh A., Larsson B., von Heijne G., Sonnhammer E.L. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 2001, 305:567-580.
30. Kyte J., Doolittle R.F. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982, 157:105-132.
31. Hu Z., Mellor J., Wu J., DeLisi C. VisANT: an online visualization and analysis tool for biological interaction data. BMC Bioinformatics 2004, 5:17.
32. Hu Z., Mellor J., Wu J., Yamada T., Holloway D., Delisi C. VisANT: data-integrating visual framework for biological networks and modules. Nucleic Acids Res 2005, 33:W352-W357. [Web Server issue].
33. Cheng A.L., Huang W.G., Chen Z.C., Peng F., Zhang P.F., Li M.Y., et al. Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res 2008, 14:435-445.
34. Harder T., Engelhardt K.R. Membrane domains in lymphocytes - from lipid rafts to protein scaffolds. Traffic 2004, 5:265-275.
35. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998, 14:111-136.
36. Galbiati F., Razani B., Lisanti M.P. Emerging themes in lipid rafts and caveolae. Cell 2001, 106:403-411.
37. Hooper N.M. Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Mol Membr Biol 1999, 16:145-156.
38. Lajoie P., Nabi I.R. Lipid rafts, caveolae, and their endocytosis. Int Rev Cell Mol Biol 2010, 282:135-163.
39. Volonte D., Galbiati F., Li S., Nishiyama K., Okamoto T., Lisanti M.P. Flotillins/ cavatellins are differentially expressed in cells and tissues and form a hetero-oligomeric complex with caveolins in vivo. Characterization and epitope-mapping of a novel flotillin-1 monoclonal antibody probe. J Biol Chem 1999, 274:12702-12709.
40. Bickel P.E., Scherer P.E., Schnitzer J.E., Oh P., Lisanti M.P., Lodish H.F. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 1997, 272:13793-13802.
41. Lin C., Wu Z., Lin X., Yu C., Shi T., Zeng Y., et al. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res 2011, 17:3089-3099.
42. Hazarika P., McCarty M.F., Prieto V.G., George S., Babu D., Koul D., et al. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res 2004, 64:7361-7369.
43. Raimondo F., Valerio D.T., Magni F., Perego R., Bianchi C., Sarto C., et al. Caveolin-1 and Flotillin-1 differential expression in clinical samples of renal cell carcinoma. Open Proteomics J 2008, 1:87-98.
44. Okamoto T., Schlegel A., Scherer P.E., Lisanti M.P. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998, 273:5419-5422.
45. Liu P., Rudick M., Anderson R.G. Multiple functions of caveolin-1. J Biol Chem 2002, 277:41295-41298.
46. Wiechen K., Diatchenko L., Agoulnik A., Scharff K.M., Schober H., Arlt K., et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol 2001, 159:1635-1643.
47. Bender F.C., Reymond M.A., Bron C., Quest A.F. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000, 60:5870-5878.
48. Lee S.W., Reimer C.L., Oh P., Campbell D.B., Schnitzer J.E. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998, 16:1391-1397.
49. Fiucci G., Ravid D., Reich R., Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002, 21:2365-2375.
50. Suzuoki M., Miyamoto M., Kato K., Hiraoka K., Oshikiri T., Nakakubo Y., et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002, 87:1140-1144.
51. Kato K., Hida Y., Miyamoto M., Hashida H., Shinohara T., Itoh T., et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 2002, 94:929-933.
52. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998, 4:1873-1880.
53. Nasu Y., Timme T.L., Yang G., Bangma C.H., Li L., Ren C., et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998, 4:1062-1064.
54. Sunaga N., Miyajima K., Suzuki M., Sato M., White M.A., Ramirez R.D., et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004, 64:4277-4285.
55. Ho C.C., Huang P.H., Huang H.Y., Chen Y.H., Yang P.C., Hsu S.M. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 2002, 161:1647-1656.
56. Li M., Chen H., Diao L., Zhang Y., Xia C., Yang F. Caveolin-1 and VEGF-C promote lymph node metastasis in the absence of intratumoral lymphangiogenesis in non-small cell lung cancer. Tumori 2010, 96:734-743.
57. Cassoni P., Daniele L., Maldi E., Righi L., Tavaglione V., Novello S., et al. Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology 2009, 55:20-27.
58. Yoo S.H., Park Y.S., Kim H.R., Sung S.W., Kim J.H., Shim Y.S., et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003, 42:195-202.